吉贝尔涨2.08%，成交额3090.82万元，主力资金净流出238.98万元

Group 1 - The core viewpoint of the news is that Jibeier's stock has shown significant fluctuations, with a year-to-date increase of 55.07% but a recent decline over the past five and twenty trading days [1] - As of October 16, Jibeier's stock price was 33.93 CNY per share, with a market capitalization of 6.767 billion CNY [1] - The company has experienced a net outflow of main funds amounting to 2.3898 million CNY, while large orders showed a mixed trend with buying at 5.0187 million CNY and selling at 8.2008 million CNY [1] Group 2 - For the first half of 2025, Jibeier reported a revenue of 455 million CNY, reflecting a year-on-year growth of 4.90%, and a net profit attributable to shareholders of 149 million CNY, which is a 22.38% increase compared to the previous year [2] - The company has distributed a total of 476 million CNY in dividends since its A-share listing, with 296 million CNY distributed over the last three years [3] Group 3 - Jibeier's main business includes drug research, production, and sales, with the primary revenue sources being Likujun tablets (72.72%), Niquinlor tablets (14.20%), and Yupingfeng capsules (4.88%) [1] - The company is categorized under the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and preparations, and is involved in innovative drugs and cancer treatment [1]